Andina Capital Management LLC Takes $330,000 Position in Johnson & Johnson $JNJ

Andina Capital Management LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 1,988 shares of the company’s stock, valued at approximately $330,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Highline Wealth Partners LLC raised its position in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the first quarter valued at approximately $49,000. Capital A Wealth Management LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $50,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in Johnson & Johnson in the first quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on JNJ shares. UBS Group boosted their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 17th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an “equal weight” rating in a research report on Thursday, July 17th. Guggenheim reiterated a “neutral” rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Leerink Partners cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Nine analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $174.50.

Johnson & Johnson Stock Down 0.2%

Shares of JNJ opened at $176.26 on Tuesday. The firm has a market capitalization of $424.49 billion, a P/E ratio of 18.85, a P/E/G ratio of 2.25 and a beta of 0.41. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $177.57. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The firm has a fifty day moving average price of $161.70 and a 200-day moving average price of $158.60.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same period in the previous year, the firm earned $2.82 earnings per share. The business’s revenue was up 5.8% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson’s dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.